{"generic":"Umeclidinium","drugs":["Incruse Ellipta","Umeclidinium"],"mono":{"0":{"id":"jybms0","title":"Generic Names","mono":"Umeclidinium"},"1":{"id":"jybms1","title":"Dosing and Indications","sub":[{"id":"jybms1b4","title":"Adult Dosing","mono":"<b>Chronic obstructive pulmonary disease:<\/b> 62.5 mcg (1 inhalation) ORAL INHALATION once daily "},{"id":"jybms1b5","title":"Pediatric Dosing","mono":"safety and efficacy not established "},{"id":"jybms1b6","title":"Dose Adjustments","mono":"<ul><li><b>renal:<\/b> no dose adjustment required<\/li><li><b>hepatic, moderate:<\/b> no dose adjustment required<\/li><li><b>geriatric:<\/b> no dose adjustment required<\/li><\/ul>"},{"id":"jybms1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Chronic obstructive pulmonary disease<br\/>"}]},"3":{"id":"jybms3","title":"Contraindications\/Warnings","sub":[{"id":"jybms3b9","title":"Contraindications","mono":"<ul><li>severe hypersensitivity to milk proteins<\/li><li>hypersensitivity to umeclidinium or any product component<\/li><\/ul>"},{"id":"jybms3b10","title":"Precautions","mono":"<ul><li>Immunologic:<\/li><li>-- hypersensitivity reactions may occur<\/li><li>Ophthalmic:<\/li><li>-- worsening narrow-angle glaucoma may occur; monitoring recommended<\/li><li>Renal:<\/li><li>-- worsening urinary retention may occur, especially in patients with prostatic hyperplasia or bladder-neck obstruction; monitoring recommended<\/li><li>Respiratory:<\/li><li>-- acute bronchospasm; avoid use<\/li><li>-- loss of bronchoconstriction control may indicate disease deterioration; immediate reevaluation recommended<\/li><li>-- life-threatening paradoxical bronchospasm may occur; symptomatic treatment and discontinuation required<\/li><li>Concomitant Use:<\/li><li>-- avoid coadministration with other anticholinergics<\/li><\/ul>"},{"id":"jybms3b11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"jybms3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"jybms4","title":"Drug Interactions","sub":{"1":{"id":"jybms4b14","title":"Major","mono":"<ul><li>Amitriptyline (theoretical)<\/li><li>Amoxapine (theoretical)<\/li><li>Atropine (theoretical)<\/li><li>Belladonna (theoretical)<\/li><li>Benztropine (theoretical)<\/li><li>Biperiden (theoretical)<\/li><li>Brompheniramine (theoretical)<\/li><li>Bupropion (theoretical)<\/li><li>Carbinoxamine (theoretical)<\/li><li>Carisoprodol (theoretical)<\/li><li>Chlorpheniramine (theoretical)<\/li><li>Chlorpromazine (theoretical)<\/li><li>Clemastine (theoretical)<\/li><li>Clidinium (theoretical)<\/li><li>Clomipramine (theoretical)<\/li><li>Clozapine (theoretical)<\/li><li>Cyclobenzaprine (theoretical)<\/li><li>Cyclopentolate (theoretical)<\/li><li>Cyproheptadine (theoretical)<\/li><li>Darifenacin (theoretical)<\/li><li>Desipramine (theoretical)<\/li><li>Dicyclomine (theoretical)<\/li><li>Dimenhydrinate (theoretical)<\/li><li>Diphenhydramine (theoretical)<\/li><li>Donepezil (theoretical)<\/li><li>Doxepin (theoretical)<\/li><li>Fesoterodine (theoretical)<\/li><li>Flavoxate (theoretical)<\/li><li>Fluphenazine (theoretical)<\/li><li>Glycopyrrolate (theoretical)<\/li><li>Homatropine (theoretical)<\/li><li>Hydroxyzine (theoretical)<\/li><li>Hyoscyamine (theoretical)<\/li><li>Imipramine (theoretical)<\/li><li>Ipratropium (theoretical)<\/li><li>Loratadine (theoretical)<\/li><li>Loxapine (theoretical)<\/li><li>Meclizine (theoretical)<\/li><li>Mepenzolate (theoretical)<\/li><li>Morphine (theoretical)<\/li><li>Morphine Sulfate Liposome (theoretical)<\/li><li>Nortriptyline (theoretical)<\/li><li>Olanzapine (theoretical)<\/li><li>Orphenadrine (theoretical)<\/li><li>Oxitropium Bromide (theoretical)<\/li><li>Oxybutynin (theoretical)<\/li><li>Oxymorphone (probable)<\/li><li>Paroxetine (theoretical)<\/li><li>Perphenazine (theoretical)<\/li><li>Pimozide (theoretical)<\/li><li>Pipenzolate Bromide (theoretical)<\/li><li>Pirenzepine (theoretical)<\/li><li>Prochlorperazine (theoretical)<\/li><li>Procyclidine (theoretical)<\/li><li>Promethazine (theoretical)<\/li><li>Propantheline (theoretical)<\/li><li>Propiverine (theoretical)<\/li><li>Protriptyline (theoretical)<\/li><li>Scopolamine (theoretical)<\/li><li>Solifenacin (theoretical)<\/li><li>Stramonium (theoretical)<\/li><li>Terodiline (theoretical)<\/li><li>Thioridazine (theoretical)<\/li><li>Thiothixene (theoretical)<\/li><li>Tiotropium (theoretical)<\/li><li>Tizanidine (theoretical)<\/li><li>Tolterodine (theoretical)<\/li><li>Trifluoperazine (theoretical)<\/li><li>Trihexyphenidyl (theoretical)<\/li><li>Trimipramine (theoretical)<\/li><li>Tropicamide (theoretical)<\/li><li>Trospium (theoretical)<\/li><\/ul>"}}},"5":{"id":"jybms5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Respiratory:<\/b>Nasopharyngitis (8%), Upper respiratory infection (5%)<br\/><b>Serious<\/b><ul><li><b>Immunologic:<\/b>Anaphylaxis<\/li><li><b>Ophthalmic:<\/b>Angle-closure glaucoma<\/li><li><b>Renal:<\/b>Urinary retention<\/li><li><b>Respiratory:<\/b>Paradoxical bronchospasm<\/li><\/ul>"},"6":{"id":"jybms6","title":"Drug Name Info","sub":{"0":{"id":"jybms6b17","title":"US Trade Names","mono":"Incruse Ellipta<br\/>"},"2":{"id":"jybms6b19","title":"Class","mono":"<ul><li>Antimuscarinic<\/li><li>Respiratory Agent<\/li><\/ul>"},"3":{"id":"jybms6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jybms6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"jybms7","title":"Mechanism Of Action","mono":"Umeclidinium is an anticholinergic that causes bronchodilation by inhibiting the M3 receptors on the smooth muscle of the airways.<br\/>"},"8":{"id":"jybms8","title":"Pharmacokinetics","sub":[{"id":"jybms8b23","title":"Absorption","mono":"Tmax, Inhalation: 5 to 15 minutes <br\/>"},{"id":"jybms8b24","title":"Distribution","mono":"<ul><li>Protein binding: 89%<\/li><li>Vd: 86 L<\/li><\/ul>"},{"id":"jybms8b25","title":"Metabolism","mono":"<ul><li>metabolism: oxidation followed by conjugation<\/li><li>substrate of CYP2D6 and P-glycoprotein<\/li><\/ul>"},{"id":"jybms8b26","title":"Excretion","mono":"<ul><li>Renal: less than 1% (oral) to 22% (IV)<\/li><li>Fecal: 58% (IV) to 92% (oral)<\/li><\/ul>"},{"id":"jybms8b27","title":"Elimination Half Life","mono":"11 hours <br\/>"}]},"9":{"id":"jybms9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>for oral inhalation only<br\/><\/li><li><b>Inhalation, oral<\/b><br\/><ul><li>administer at the same time every day<\/li><li>opening and closing the device without an inhalation will result in a lost dose<\/li><li>when ready for a dose, open the cover of the inhaler; a click will be heard and the counter will decrease to indicate the device is ready<\/li><li>before inhaling the dose, breathe out fully; do not exhale into the device<\/li><li>place device firmly between lips and inhale with a long, deep, steady breath through the mouth; do not breathe in through nose or cover air vent on the inhaler<\/li><li>hold breath for 3 to 4 seconds or for as long as comfortable, and exhale slowly<\/li><li>inhalation device is not reusable; discard 6 weeks after opening, or when dose counter reads zero (whichever comes first)<\/li><\/ul><\/li><\/ul>"},"10":{"id":"jybms10","title":"Monitoring","mono":"<ul><li>improvement or maintenance of respiratory function in patients with COPD may indicate efficacy<\/li><li>respiratory function, with symptoms suggestive of disease deterioration<\/li><\/ul>"},"11":{"id":"jybms11","title":"How Supplied","mono":"<b>Incruse Ellipta<\/b><br\/>Inhalation Powder: 62.5 MCG\/Actuation<br\/>"},"13":{"id":"jybms13","title":"Clinical Teaching","mono":"<ul><li>Instruct patient to seek immediate medical attention if their symptoms get worse or if they need more inhalations from their rescue inhaler than usual.<\/li><li>Advise patient that drug is not to be used to relieve acute symptoms and extra doses should not be used for that purpose. Instruct patient to treat acute symptoms with a short-acting beta-agonist rescue inhaler..<\/li><li>Side effects may include nasopharyngitis, upper respiratory tract infection, cough, joint pain, muscle pain, or upper abdominal pain.<\/li><li>Advise patient to report signs\/symptoms of acute narrow-angle glaucoma (eg, eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema).<\/li><li>Instruct patient to report signs\/symptoms of urinary retention (eg, difficulty passing urine, painful urination).<\/li><li>Instruct patient to take drug at the same time every day and not use it more than once every 24 hours.<\/li><li>Advise patient on proper preparation of the delivery device, and inhalation technique.<\/li><li>Advise patient that there are multiple significant drug-drug interactions for this drug. Consult a healthcare professional prior to new drug use (including over-the-counter and herbal drugs).<\/li><\/ul>"}}}